

Table of Contents

Acknowledgements		
Committees		v7
Financial Support		v7
Summary of Conference Schedule		v9
Satellite Symposia Schedule		v13
Conference Schedule		v15
Abstracts		
Opening Ceremony		
001	Henry Kaplan Memorial Lecture	v27
Oral Presentations		
002-007	1. Virology, Epidemiology	v28
008-013	2. Multiple Myeloma	v30
014-015	3. What is the Role of High Dose Chemotherapy for Follicular Lymphoma?	v32
016-019	4. Immunotherapy	v33
020-023	5. Biology of Lymphomas I	v35
024-030	6. Biology of Lymphomas II	v36
031	7. Henry Rappaport Memorial Lecture - Key Note Lecture I	v39
032-035	8. Review Lectures on Hodgkin's Disease	v40
036-043	9. Chronic Lymphocytic Leukaemia	v42
044-045	10. Is R-CHOP the Standard Treatment for DLCL?	v45
046-050	11. 10 Years WHO Classification	v46
051-055	12. Mantle Cell Lymphoma	v48
056	13. John Ultmann Memorial Lecture - Key Note Lecture II	v50
057-063	14. Clinical Results in Lymphoma I	v51
064-074	15. Clinical Results in Lymphoma I	v54
075-084	16. Clinical-Pathological Correlations	v58
085-093	17. Paediatric Lymphomas	v61
094	18. Lymphoma Transformation	v64
095-102	19. New Agents	v65
103-109	20. New Treatment Modalities	v68
110-118	21. New Immunological Principles	v70

Posters**Poster session I**

119-154	1. Biology/Genetics/Immunology	v73
155-164	2. Biology of Hodgkin's Disease	v83
165-184	3. CLL/Multiple Myeloma	v86
185-195	4. Extranodal Lymphomas I	v92
196-229	5. Aggressive Lymphomas	v95

Poster session II

230-259	6. Indolent Lymphomas	v105
260-279	7. Hodgkin's Disease	v114
280-289	8. Role of PET	v120
290-303	9. Extranodal Lymphomas II	v123
304-323	10. T-cell Lymphoma/HIV-Lymphoma	v127
324-327	11. Pediatric Lymphomas	v133
328-340	12. New Treatments	v134

Further Abstracts

341-347	1. Virology/Epidemiology	v138
348-365	2. Biology/Genetics	v140
366-373	3. Imaging	v145
374-410	4. Indolent Lymphomas	v148
411-443	5. Extranodal Lymphomas	v159
444-457	6. Mantle Cell Lymphomas	v168
458-510	7. Diffuse Large Cell Lymphomas (DLCL)	v172
511-523	8. T-cell Lymphomas/Lymphomas in AIDS	v187
524-554	9. Hodgkin's Disease	v191
555-579	10. CLL/Multiple Myeloma	v200
580-595	11. New Treatments/New Drugs	v207
596-602	12. Pediatric Lymphomas	v212
603-627	13. Miscellaneous	v214

Author Index

v221

Subject Index

v237

Schedules and Abstracts of Satellite Symposia

v243

Annals of Oncology

Official Journal of the European Society for Medical Oncology

Editor-in-Chief:

D. J. Kerr, *Oxford, UK*

Associate Editors:

M. S. Aapro, *Genolier, Switzerland*
J. O. Armitage, *Omaha, Nebraska, USA*
J. Baselga, *Barcelona, Spain*
P. Boyle, *Lyon, France*
M. Castiglione-Gertsch, *Berne, Switzerland*
V. Diehl, *Cologne, Germany*
R. Labianca, *Bergamo, Italy*
T. Le Chevalier, *Villejuif, France*
C. J. A. Punt, *Nijmegen, The Netherlands*
N. Thatcher, *Manchester, UK*
J. B. Vermorken, *Edegem, Belgium*

Editor Emeritus:

F. Cavalli, *Bellinzona, Switzerland*

Editorial Board

K. Antman, <i>New York, USA</i>	S. B. Kaye, <i>Sutton, UK</i>	A. Roth, <i>Geneva, Switzerland</i>
J.-P. Armand, <i>Villejuif, France</i>	C.-H. Köhne, <i>Dresden, Germany</i>	P. Rougier, <i>Boulogne, France</i>
M. Bendandi, <i>Pamplona, Spain</i>	P. A. Kosmidis, <i>Athens, Greece</i>	E. K. Rowinsky, <i>San Antonio, Texas, USA</i>
M. Björkholm, <i>Stockholm, Sweden</i>	A. S. Lichter, <i>Ann Arbor, MI, USA</i>	N. Saijo, <i>Tokyo, Japan</i>
C. Bokemeyer, <i>Hamburg, Germany</i>	A. T. Lister, <i>London, UK</i>	H.-J. Schmoll, <i>Halle, Germany</i>
G. Bonadonna, <i>Milan, Italy</i>	F. Mandelli, <i>Rome, Italy</i>	G. Schwartzmann, <i>Porto Alegre, Brazil</i>
F. Cabanillas, <i>Houston, Texas, USA</i>	G. Masera, <i>Monza, Italy</i>	C. N. Sternberg, <i>Rome, Italy</i>
C. J. Castro, <i>Bogotá, Columbia</i>	R. J. Mayer, <i>Boston, Massachusetts, USA</i>	G. Stoter, <i>Rotterdam, The Netherlands</i>
A. S. Coates, <i>Sydney, Australia</i>	F. M. Muggia, <i>New York, USA</i>	M. Tonato, <i>Perugia, Italy</i>
J. M. Connors, <i>Vancouver, Canada</i>	J. P. Neijt, <i>Utrecht, The Netherlands</i>	T. Tursz, <i>Villejuif, France</i>
H. Cortés-Funes, <i>Madrid, Spain</i>	K. Öberg, <i>Uppsala, Sweden</i>	E. Van Cutsem, <i>Leuven, Belgium</i>
L. H. Einhorn, <i>Indianapolis, Indiana, USA</i>	S. Pavlovsky, <i>Buenos Aires, Argentina</i>	A. T. Van Oosterom, <i>Leuven, Belgium</i>
E. A. Eisenhauer, <i>Kingston, Canada</i>	G. J. Peters, <i>Amsterdam, The Netherlands</i>	E. E. Vokes, <i>Chicago, Illinois, USA</i>
B. Glimelius, <i>Uppsala, Sweden</i>	M. Pfreundschuh, <i>Homburg/Saar, Germany</i>	D. A. Vorobiof, <i>Johannesburg, South Africa</i>
A. Goldhirsch, <i>Milan, Italy</i>	M. Piccart, <i>Brussels, Belgium</i>	C. Williams, <i>Oxford, UK</i>
H. H. Hansen, <i>Copenhagen, Denmark</i>	H. M. Pinedo, <i>Amsterdam, The Netherlands</i>	J. Zalcberg, <i>Melbourne, Australia</i>
A. L. Harris, <i>Oxford, UK</i>	V. Raina, <i>New Delhi, India</i>	
W. Hiddemann, <i>Munich, Germany</i>	R. Rosell, <i>Badalona, Spain</i>	
D. K. Hossfeld, <i>Hamburg, Germany</i>		
H. Jürgens, <i>Munster, Germany</i>		

Executive Editor: Lewis Rowett

Editorial Office: Annals of Oncology, Via la Santa 7, CH-6962 Viganello-Lugano, Switzerland

Annals of Oncology is devoted to the rapid circulation of scientific communications concerning oncology, particularly medical oncology. Its character, however, is multidisciplinary, in reflection of the proliferation of activities and interests in Europe, and contributions on clinically oriented laboratory research, surgery and radiotherapy are assured by the presence of representatives of these disciplines on the Editorial Committee and Board.

Annals of Oncology is covered in C.A.B. International, Current Clinical Cancer, Current Contents/Clinical Medicine®, Current Contents/Life Sciences, Elsevier BIOBASE/Current Awareness in Biological Sciences, EMBASE/Excerpta Medica, IBIDS, Index Medicus/MEDLINE, The International Monitor in Oncology, Medical Documentation Service, Science Citation Index® and Science Citation Index Expanded.

Annals of Oncology

SUBSCRIPTIONS

A subscription to *Annals of Oncology* comprises 12 issues plus supplements, with an Annual Author and Keyword Index in each volume. Prices include postage, and for subscribers outside the UK delivery is by Standard Air.

Annual Subscription Rate (Volume 16, 12 issues, 2005)

Institutional

Print edition and site-wide online access: £813/€1220/\$1382

Print edition only: £772/€1158/\$1312

Site-wide online access only: £732/€1098/\$1244

Personal

Print edition and individual online access: £772/€1158/\$1312

Please note: £ Sterling and Euro rates apply in Europe, US\$ elsewhere

There may be other subscription rates available, for a complete listing please visit www.annonc.oupjournals.org/subinfo/.

Full prepayment, in the correct currency, is required for all orders. Orders are regarded as firm and payments are not refundable. Subscriptions are accepted and entered on a complete volume basis. Claims cannot be considered more than FOUR months after publication or date of order, whichever is later. All subscriptions in Canada are subject to GST. Subscriptions in the EU may be subject to European VAT. If registered, please supply details to avoid unnecessary charges. For subscriptions that include online versions, a proportion of the subscription price may be subject to UK VAT. Personal rate subscriptions are only available if payment is made by personal cheque or credit card and delivery is to a private address.

The current year and two previous years' issues are available from Oxford University Press. Previous volumes can be obtained from the Periodicals Service Company, 11 Main Street, Germantown, NY 12526, USA. Email: psc@periodicals.com. Tel: +1 (518) 537 4700. Fax: +1 (518) 537 5899.

For further information, please contact: Journals Customer Service Department, Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Email: jnls.cust.serv@oupjournals.org. Tel (and answerphone outside normal working hours): +44 (0)1865 353907. Fax: + 44 (0)1865 353485. **In the US, please contact:** Journals Customer Service Department, Oxford University Press, 2001 Evans Road, Cary, NC 27513, USA. Email: jnlorders@oupjournals.org. Tel (and answerphone outside normal working hours): 800 852 7323 (toll-free in USA/Canada). Fax: 919 677 1714. **In Japan, please contact:** Journals Customer Services, Oxford University Press, 1-1-17-5F, Mukogaoka, Bunkyo-ku, Tokyo, 113-0023, Japan. Email: okudaoup@po.ijnet.or.jp. Tel: (03) 3813 1461. Fax: (03) 3818 1522.

Methods of payment. Payment may be made by cheque (payable to Oxford University Press) in £ sterling drawn on a UK bank or in US\$ drawn on a US bank, bank transfer (£ sterling – Barclays Bank Plc, Oxford City Office, PO Box 333, Oxford, OX1 3HS, UK. Bank sort code: 20-65-18, Account No. 70299332, IBAN number GB89BARC20651870299332, Swift code BARCGB22), or by credit card (Mastercard, Visa, Switch or American Express).

Annals of Oncology (ISSN 0923-7534) is published monthly by Oxford University Press, Oxford, UK. Annual print subscription price is £772/€1158/\$1312. *Annals of Oncology* is distributed by Mercury International, 365 Blair Road, Avenel, NJ 07001, USA. Periodicals postage paid at Rahway, NJ and at additional entry points.

US Postmaster: send address changes to *Annals of Oncology* (ISSN 0923-7534), c/o Mercury International, 365 Blair Road, Avenel, NJ 07001, USA.

Supplements, reprints and corporate sales

For requests from industry and companies regarding supplements, bulk article reprints, sponsored subscriptions, translation opportunities for previously published material, and corporate online opportunities, please email special.sales@oupjournals.org, fax: +44 (0)1865 353774 or visit www.oupjournals.org/sales.

Permissions

For information on how to request permissions to reproduce articles/information from this journal, please visit www.oupjournals.org/permissions.

Advertising

Inquiries about advertising should be sent to Peter Carpenter, PRC Associates. Email: mail@prcassoc.co.uk. Fax: +44 (0)20 8786 7262.

Drug disclaimer

All reasonable precautions have been taken by the authors, editors and publisher to verify drug names and doses, the results of experimental work and the clinical findings published in this journal. The opinions expressed are those of the authors, and not necessarily those of the editors or publisher. The ultimate responsibility for the use and dosage of drugs mentioned in *Annals of Oncology* and in the interpretation of published material lies with the medical practitioner. The editors and publisher can accept no liability whatsoever in respect of any claim for damages arising therefrom. Please inform the editors of any errors.

© The European Society for Medical Oncology 2005

All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission of the Publishers, or a licence permitting restricted copying issued in the UK by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1P 9HE, or in the USA by the Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923.

Typeset by the Alden Group, Oxford, UK
Printed by Latimer Trend & Co Ltd, Plymouth, UK

Acknowledgements

Committees

Conference President

F. Cavalli, Bellinzona, Switzerland

International Organizing Committee

F. Cavalli (Bellinzona, Switzerland)

J. O. Armitage (Omaha, USA)

M. Björkholm (Stockholm, Sweden)

B. Coiffier (Pierre Bénite, France)

M. Ghielmini (Bellinzona, Switzerland)

W. Hiddemann (Munich, Germany)

T. A. Lister (London, UK)

E. Zucca (Bellinzona, Switzerland)

Scientific Advisory Board

G. P. Canellos (Boston, USA)

J. M. Connors (Vancouver, Canada)

F. E. Cotter (London, UK)

R. Dalla-Favera (New York, USA)

V. Diehl (Cologne, Germany)

J. L. Harousseau (Nantes, France)

S. J. Horning (Palo Alto, USA)

P.W.M.Johnson (Southampton, UK)

M. J. Keating (Houston, USA)

S. J. Korsmeyer (Boston, USA)

A. Lanzavecchia (Bellinzona, Switzerland)

R. Levy (Stanford, USA)

D. L. Longo (Baltimore, USA)

E. Montserrat (Barcelona, Spain)

S. B. Murphy (San Antonio, USA)

S. Pavlovsky (Buenos Aires, Argentina)

S. A. Pileri (Bologna, Italy)

J. A. Radford (Manchester, UK)

J. C. Reed (La Jolla, USA)

J. L. Schultze (Cologne, Germany)

M. A. Shipp (Boston, USA)

L. M. Staudt (Bethesda, USA)

H. Stein (Berlin, Germany)

K. Tobinai (Tokyo, Japan)

Local Organization and Conference Secretariat

O. Jackson, C. Brentan, A. Amato

Lugano, Switzerland

Financial Support

The conference organizers wish to thank the following sponsors for their financial support:

Amgen (Europe) GmbH

American Society of Clinical Oncology

Astra Zeneca AG

Baxter Oncology GmbH

Bristol Myers Squibb Switzerland

Cancer Genetics, Inc.

Chugai-Aventis

City of Lugano

EuroGen Pharmaceuticals Ltd.

European School of Oncology

GlaxoSmithKline AG

Helsinn Healthcare SA

International Waldenström's Macroglobulinemia Foundation

Lilly Oncology

Lipomed AG

Millennium Pharmaceuticals Inc.

MSD Oncology

Mundipharma International

Novartis Pharma Schweiz AG

Ortho Biotech

Pfizer Oncology

Ribosepharm

Roche

S. Karger AG

Sanofi-Synthelabo Groupe

Schering AG

Sodiag AG

SuperGen, Inc.

Swiss Int. Airlines Ltd.

Swiss League Against Cancer

Ticino Turismo

Zeneus Pharma Ltd.

Abstract Book of the 9th International Conference on Malignant Lymphoma

LUGANO, SWITZERLAND

8-11 JUNE 2005

Printed copies of the meeting abstracts have been provided for Conference Delegates only. However, the abstracts are available on-line to all Annals of Oncology subscribers and are also freely available to all visitors to the following website from the date of the meeting (<http://annonc.oupjournals.org>).

A limited number of print copies are available and may be ordered from ICML
(Email: olga.jackson@lymphcon.ch)

Notice:

The content of the abstracts contained in this Abstract Book is subject to an embargo on publication till the relating presentation is given at the 9th ICML. Abstracts that are published in the abstract book but that will not be presented at the congress are embargoed until 8:00 hours of 8 June 2005.

Disclaimer:

No responsibility is assumed by the organizers for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in medical sciences, we recommend that independent verification of diagnoses and drug dosages should be made.

Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the organizers for any omissions or misprints.